Startup profile · funding coverage
Link Cell Therapies funding, valuation and investors
Logic-gated CAR-T company that added a $30 million extension, increasing its Series A to $90 million.
Keep track of Link Cell Therapies
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A extension
$30M extension; $90M total Series A · September 29, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$30M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Investors in latest funding
Other: Johnson & Johnson Innovation
Overview
Link Cell Therapies develops logic-gated CAR-T therapies for solid tumors. In late September 2026 the company began clinical dosing of LNK001 and upsized its Series A to $90 million. Public reporting describes the latest financing as a $30 million extension to the existing Series A.
Why Link Cell Therapies is interesting
Clinical dosing and financing expansion happened together; the correct funding interpretation is a $30M extension to a $90M Series A, not a new $90M round.
Key facts
- Sep 2026: $30M extension increased Series A to $90M
- Company began Phase 1 dosing of LNK001
Funding history (newest first)
Series A extension
2026-09-29 $30M extension; $90M total Series A- Johnson & Johnson Innovation (participant)
Source: https://thehealthtechsignal.com/article/link-cell-lnk001-two-marker-car-t
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.